MAIA Biotechnology, Inc. MAIA opened up its shares for public trading for the first time since it filed for IPO in April 2022. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share. On its first day of trading, the stock increased 8.78% from its opening price of $4.1 to its closing price of $4.46.
MAIA Biotechnology, Inc. Performance On First Day of Trading
About MAIA Biotechnology, Inc. and It’s IPO
MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
For its IPO, MAIA agreed to offer 2.00 million shares at a price of $5.00 per share, with an insider lock-up period of 180 days, ending on January 24, 2023.
An insider lock-up period is a period of time after a company first goes public where major shareholders are not allowed to sell their shares. The insider lock-up period makes sure that the market does not get oversupplied with shares of the company.
Traders may short the stock leading up to the lockup-period expiration date in hopes that the price will fall due to an increase in supply of shares. Retail traders should be watching this stock’s short interest as it moves closer to lockup expiration.
See also: Benzinga’s Most Shorted Stocks
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Image and article originally from www.benzinga.com. Read the original article here.